在新型冠状病毒肺炎防治中，中医药在阻断病情发展、降低重症率和病亡率、助力愈后功能恢复等方面发挥了重要作用，有力推动了我国中医药产业发展。国家药品审评中心注册数据显示，2021年是近10年来中药注册量最大的1年；湖北、山东、吉林等地制药公司表现最为活跃；目标适应症聚焦在消化代谢和呼吸系统等传统优势领域；90%以上注册件已完成审批；59种新药中有6种报产，且至检索日已有3种获批。这些数据表明我国中药企业研发积极性明显提高，新药研究愈加活跃。中药研发呈现出的积极向好的新态势将有助于开发出更多优质中药，有效缓解临床需求，更好保障人民健康。

In the prevention and treatment of novel coronavirus pneumonia, traditional Chinese medicine (TCM) has played an important role in blocking the development of the disease, reducing the severity and fatality rate, and also helping the functional recovery after infection, which has strongly promoted the development of TCM industry in China. The registration data from the Center for Drug Evaluation shows that 2021 is the largest year for TCM registration in the past 10 years. Pharmaceutical companies in Hubei, Shandong and Jilin are the most active. The target indications are focused on traditional dominant areas, such as digestion and metabolism diseases, respiratory system, more than 90% of registrations have been approved. Six out of 59 new have been reported for production and three drugs have been approved until the retrieval date. These data show that the enthusiasm for the development of TCM was significantly improved, new drug research has become more active. This positive new development trend will help to develop more high-quality TCM, greatly alleviate clinical needs and better protect people’s health.

国家自然科学基金资助项目(81873183)